DexCom, Inc. (DXCM) CFO Jess Roper Sells 2,000 Shares

DexCom, Inc. (NASDAQ:DXCM) CFO Jess Roper sold 2,000 shares of DexCom stock in a transaction dated Wednesday, March 22nd. The shares were sold at an average price of $75.97, for a total transaction of $151,940.00. Following the transaction, the chief financial officer now owns 46,497 shares of the company’s stock, valued at $3,532,377.09. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Jess Roper also recently made the following trade(s):

  • On Wednesday, January 18th, Jess Roper sold 3,012 shares of DexCom stock. The shares were sold at an average price of $85.01, for a total transaction of $256,050.12.

Shares of DexCom, Inc. (NASDAQ:DXCM) traded up 0.91% during mid-day trading on Monday, reaching $83.37. 496,392 shares of the company’s stock traded hands. The firm’s 50 day moving average price is $79.25 and its 200-day moving average price is $76.56. The stock’s market cap is $7.07 billion. DexCom, Inc. has a 12-month low of $57.68 and a 12-month high of $96.38.

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

COPYRIGHT VIOLATION WARNING: “DexCom, Inc. (DXCM) CFO Jess Roper Sells 2,000 Shares” was first posted by Mideast Time and is the sole property of of Mideast Time. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://www.mideasttime.com/dexcom-inc-dxcm-cfo-jess-roper-sells-2000-shares/1589518.html.

Hedge funds have recently made changes to their positions in the stock. Ladenburg Thalmann Financial Services Inc. increased its stake in shares of DexCom by 2.0% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 5,596 shares of the medical device company’s stock valued at $337,000 after buying an additional 112 shares during the period. Bbva Compass Bancshares Inc. increased its stake in shares of DexCom by 6.5% in the third quarter. Bbva Compass Bancshares Inc. now owns 3,944 shares of the medical device company’s stock valued at $346,000 after buying an additional 240 shares during the period. Pacer Advisors Inc. increased its stake in shares of DexCom by 4.2% in the third quarter. Pacer Advisors Inc. now owns 8,620 shares of the medical device company’s stock valued at $756,000 after buying an additional 350 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of DexCom by 2.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,837 shares of the medical device company’s stock valued at $2,177,000 after buying an additional 554 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of DexCom by 37.3% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,876 shares of the medical device company’s stock valued at $252,000 after buying an additional 781 shares during the period.

Several research firms recently weighed in on DXCM. B. Riley upgraded shares of DexCom to a “buy” rating and set a $84.00 price target on the stock in a report on Tuesday, December 20th. Canaccord Genuity restated a “buy” rating and set a $95.00 price target on shares of DexCom in a report on Friday, February 10th. Wedbush restated an “outperform” rating and set a $85.00 price target on shares of DexCom in a report on Wednesday, January 11th. Oppenheimer Holdings Inc. restated a “buy” rating on shares of DexCom in a report on Wednesday, March 22nd. Finally, Northcoast Research restated a “buy” rating on shares of DexCom in a report on Wednesday, March 1st. Three investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $92.64.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.

5 Day Chart for NASDAQ:DXCM

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.